<p>Crescent Park Management L.P. 在最近向美国证券交易委员会（SEC）披露的信息中表示，其在 Cellebrite DI Ltd.（NASDAQ:CLBT - 免费报告）的持股在第二季度减少了 16.6%。该基金在此期间出售了 113,179 股后，持有 570,232 股该公司的股票。Cellebrite DI 大约占 Crescent Park Management L.P.持股的 3.5%，是其第 12 大持仓。截至最近的 SEC 文件，Crescent Park Management L.P.持有的 Cellebrite DI 的股份约占 0.24%，价值 9,124,000 美元。</p>
<p>其他几家对冲基金和机构投资者最近也对 CLBT 的持仓进行了调整。T. Rowe Price Investment Management Inc.在第一季度购买了 Cellebrite DI 的新头寸，价值约为 60,939,000 美元。Invesco Ltd.在第一季度将其在 Cellebrite DI 的股份增加了 122.1%。Invesco Ltd.现在持有 3,296,079 股该公司的股票，价值 64,043,000 美元，此前在上个季度又收购了 1,811,757 股。Phoenix Financial Ltd.在第二季度将其在 Cellebrite DI 的持股增加了 153.5%。Phoenix Financial Ltd.现在持有 2,014,617 股该公司的股票，价值 32,232,000 美元，此前在上个季度又收购了 1,219,958 股。Handelsbanken Fonder AB 在第二季度将其在 Cellebrite DI 的持仓提高了 61.3%。Handelsbanken Fonder AB 现在持有 2,450,000 股该公司的股票，价值 39,200,000 美元，此前在上个季度又购买了 931,300 股。最后，加拿大皇家银行在第一季度将其在 Cellebrite DI 的持股增加了 11,705.0%。加拿大皇家银行现在持有 824,226 股该公司的股票，价值 16,015,000 美元，此前在上个季度又购买了 817,244 股。对冲基金和其他机构投资者持有该公司 45.88% 的股票。</p>
<p>获取 <strong>Cellebrite DI</strong> 的提醒：</p>
<h2>Cellebrite DI 价格表现</h2>
<p>CLBT 股票在周二开盘价为 17.14 美元。Cellebrite DI Ltd.的 1 年最低价为 13.10 美元，1 年最高价为 26.30 美元。该公司的市值为 41 亿美元，市盈率为-22.55，市盈增长比率为 3.16，贝塔值为 1.28。该股票的 50 日移动平均价格为 17.79 美元，200 日移动平均价格为 16.50 美元。</p>
<p>Cellebrite DI（NASDAQ:CLBT - 获取免费报告）最近在 11 月 12 日（星期三）发布了季度财报。该公司报告的季度每股收益（EPS）为 0.08 美元，低于分析师一致预期的 0.13 美元，差额为 0.05 美元。该公司季度收入为 1.2603 亿美元，而分析师预期为 1.2298 亿美元。Cellebrite DI 的净利润率为-34.56%，股本回报率为 23.92%。该公司的收入较去年同期增长了 17.9%。去年同期，该公司每股收益为 0.14 美元。Cellebrite DI 已设定 2025 财年的每股收益指导。2025 年第四季度的指导为每股收益。整体来看，分析师预计 Cellebrite DI Ltd.今年的每股收益为 0.3。</p>
<h2>分析师设定新目标价</h2>
<p>多位分析师对该股票发表了看法。美国银行在 11 月 13 日（星期四）的研究报告中将 Cellebrite DI 的目标价从 24.00 美元上调至 25.00 美元，并给予该公司 “买入” 评级。摩根大通将 Cellebrite DI 的目标价从 23.00 美元上调至 24.00 美元，并在 11 月 13 日（星期四）的研究报告中给予该公司 “增持” 评级。Weiss Ratings 在 11 月 25 日（星期二）的报告中重申了对 Cellebrite DI 的 “卖出（d-）” 评级。Lake Street Capital 在 11 月 13 日（星期四）的研究报告中将 Cellebrite DI 的目标价从 22.00 美元上调至 23.00 美元，并给予该公司 “买入” 评级。最后，Needham &amp; Company LLC 在 11 月 13 日（星期四）的研究报告中将 Cellebrite DI 的目标价从 22.00 美元上调至 24.00 美元，并给予该股票 “买入” 评级。四位股票研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 24.00 美元。</p>
<p><strong>查看我们关于 CLBT 的最新报告</strong></p>
<h2>Cellebrite DI 公司简介</h2>
<p>（免费报告）</p>
<p>Cellebrite DI Ltd.为欧洲、中东、非洲、美洲和亚太地区的合法调查开发解决方案。该公司的 DI 解决方案套件允许用户在调查生命周期内收集、审查、分析和管理数字数据，涉及各种案件的合法调查，包括儿童剥削、谋杀、反恐、边境控制、性犯罪、人口贩卖、企业安全、加密货币和知识产权盗窃。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Cellebrite DI</li>
<li>投资的股票类型有不同</li>
<li>预计 2025 年上涨超过 20%，这三只股票正在提升回购能力</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>国会再次超越市场——这是他们购买的三只股票</li>
<li>消费者可选股票解析</li>
<li>与三只顶级零售 ETF 一起购物</li>
</ul>
<p><strong>想看看其他对冲基金持有的 CLBT 吗？</strong> 访问 HoldingsChannel.com 获取 Cellebrite DI Ltd.（NASDAQ:CLBT - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xCVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Cellebrite DI 吗？</h2>
<p>在你考虑 Cellebrite DI 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Cellebrite DI 并不在名单上。</p>
<p>虽然 Cellebrite DI 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CLBT

<p>Crescent Park Management L.P. 在第二季度减少了对 Cellebrite DI Ltd. 的持股比例，降幅为 16.6%，目前持有 570,232 股。其他机构投资者也调整了他们在 CLBT 的头寸。该股票开盘价为 17.14 美元，市值为 41 亿美元。分析师的评级意见不一，普遍共识为 “适度买入”，平均目标价格为 24.00 美元</p>

<p>Crescent Park Management L.P. trimmed its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 16.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 570,232 shares of the company's stock after selling 113,179 shares during the period. Cellebrite DI makes up approximately 3.5% of Crescent Park Management L.P.'s holdings, making the stock its 12th largest position. Crescent Park Management L.P. owned approximately 0.24% of Cellebrite DI worth $9,124,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Crescent Park Management L.P. 在最近向美国证券交易委员会（SEC）披露的信息中表示，其在 Cellebrite DI Ltd.（NASDAQ:CLBT - 免费报告）的持股在第二季度减少了 16.6%。该基金在此期间出售了 113,179 股后，持有 570,232 股该公司的股票。Cellebrite DI 大约占 Crescent Park Management L.P.持股的 3.5%，是其第 12 大持仓。截至最近的 SEC 文件，Crescent Park Management L.P.持有的 Cellebrite DI 的股份约占 0.24%，价值 9,124,000 美元。</p>
</div><p>Several other hedge funds and other institutional investors also recently made changes to their positions in CLBT. T. Rowe Price Investment Management Inc. bought a new position in Cellebrite DI during the 1st quarter valued at approximately $60,939,000. Invesco Ltd. grew its stake in shares of Cellebrite DI by 122.1% in the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock worth $64,043,000 after acquiring an additional 1,811,757 shares during the last quarter. Phoenix Financial Ltd. increased its holdings in shares of Cellebrite DI by 153.5% during the second quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company's stock valued at $32,232,000 after acquiring an additional 1,219,958 shares in the last quarter. Handelsbanken Fonder AB raised its position in shares of Cellebrite DI by 61.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 2,450,000 shares of the company's stock worth $39,200,000 after purchasing an additional 931,300 shares during the last quarter. Finally, Royal Bank of Canada boosted its stake in Cellebrite DI by 11,705.0% in the 1st quarter. Royal Bank of Canada now owns 824,226 shares of the company's stock worth $16,015,000 after purchasing an additional 817,244 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也对 CLBT 的持仓进行了调整。T. Rowe Price Investment Management Inc.在第一季度购买了 Cellebrite DI 的新头寸，价值约为 60,939,000 美元。Invesco Ltd.在第一季度将其在 Cellebrite DI 的股份增加了 122.1%。Invesco Ltd.现在持有 3,296,079 股该公司的股票，价值 64,043,000 美元，此前在上个季度又收购了 1,811,757 股。Phoenix Financial Ltd.在第二季度将其在 Cellebrite DI 的持股增加了 153.5%。Phoenix Financial Ltd.现在持有 2,014,617 股该公司的股票，价值 32,232,000 美元，此前在上个季度又收购了 1,219,958 股。Handelsbanken Fonder AB 在第二季度将其在 Cellebrite DI 的持仓提高了 61.3%。Handelsbanken Fonder AB 现在持有 2,450,000 股该公司的股票，价值 39,200,000 美元，此前在上个季度又购买了 931,300 股。最后，加拿大皇家银行在第一季度将其在 Cellebrite DI 的持股增加了 11,705.0%。加拿大皇家银行现在持有 824,226 股该公司的股票，价值 16,015,000 美元，此前在上个季度又购买了 817,244 股。对冲基金和其他机构投资者持有该公司 45.88% 的股票。</p>
</div><p>Get <strong>Cellebrite DI</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cellebrite DI</strong> 的提醒：</p>
</div><h2>Cellebrite DI Price Performance</h2>
<div class="lb-trans"><h2>Cellebrite DI 价格表现</h2>
</div><p>CLBT stock opened at $17.14 on Tuesday. Cellebrite DI Ltd. has a 1 year low of $13.10 and a 1 year high of $26.30. The company has a market cap of $4.10 billion, a P/E ratio of -22.55, a price-to-earnings-growth ratio of 3.16 and a beta of 1.28. The stock's fifty day moving average price is $17.79 and its 200-day moving average price is $16.50.</p>
<div class="lb-trans"><p>CLBT 股票在周二开盘价为 17.14 美元。Cellebrite DI Ltd.的 1 年最低价为 13.10 美元，1 年最高价为 26.30 美元。该公司的市值为 41 亿美元，市盈率为-22.55，市盈增长比率为 3.16，贝塔值为 1.28。该股票的 50 日移动平均价格为 17.79 美元，200 日移动平均价格为 16.50 美元。</p>
</div><p>Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.13 by ($0.05). The firm had revenue of $126.03 million for the quarter, compared to analysts' expectations of $122.98 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm's revenue was up 17.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.14 EPS. Cellebrite DI has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.</p>
<div class="lb-trans"><p>Cellebrite DI（NASDAQ:CLBT - 获取免费报告）最近在 11 月 12 日（星期三）发布了季度财报。该公司报告的季度每股收益（EPS）为 0.08 美元，低于分析师一致预期的 0.13 美元，差额为 0.05 美元。该公司季度收入为 1.2603 亿美元，而分析师预期为 1.2298 亿美元。Cellebrite DI 的净利润率为-34.56%，股本回报率为 23.92%。该公司的收入较去年同期增长了 17.9%。去年同期，该公司每股收益为 0.14 美元。Cellebrite DI 已设定 2025 财年的每股收益指导。2025 年第四季度的指导为每股收益。整体来看，分析师预计 Cellebrite DI Ltd.今年的每股收益为 0.3。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of analysts have weighed in on the stock. Bank of America raised their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, November 13th. JPMorgan Chase &amp; Co. raised their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, November 13th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Cellebrite DI in a report on Tuesday, November 25th. Lake Street Capital increased their target price on Cellebrite DI from $22.00 to $23.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, November 13th. Finally, Needham &amp; Company LLC boosted their price target on Cellebrite DI from $22.00 to $24.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $24.00.</p>
<div class="lb-trans"><p>多位分析师对该股票发表了看法。美国银行在 11 月 13 日（星期四）的研究报告中将 Cellebrite DI 的目标价从 24.00 美元上调至 25.00 美元，并给予该公司 “买入” 评级。摩根大通将 Cellebrite DI 的目标价从 23.00 美元上调至 24.00 美元，并在 11 月 13 日（星期四）的研究报告中给予该公司 “增持” 评级。Weiss Ratings 在 11 月 25 日（星期二）的报告中重申了对 Cellebrite DI 的 “卖出（d-）” 评级。Lake Street Capital 在 11 月 13 日（星期四）的研究报告中将 Cellebrite DI 的目标价从 22.00 美元上调至 23.00 美元，并给予该公司 “买入” 评级。最后，Needham &amp; Company LLC 在 11 月 13 日（星期四）的研究报告中将 Cellebrite DI 的目标价从 22.00 美元上调至 24.00 美元，并给予该股票 “买入” 评级。四位股票研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 24.00 美元。</p>
</div><p><strong>Check Out Our Latest Report on CLBT</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CLBT 的最新报告</strong></p>
</div><h2>Cellebrite DI Company Profile</h2>
<div class="lb-trans"><h2>Cellebrite DI 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.</p>
<div class="lb-trans"><p>Cellebrite DI Ltd.为欧洲、中东、非洲、美洲和亚太地区的合法调查开发解决方案。该公司的 DI 解决方案套件允许用户在调查生命周期内收集、审查、分析和管理数字数据，涉及各种案件的合法调查，包括儿童剥削、谋杀、反恐、边境控制、性犯罪、人口贩卖、企业安全、加密货币和知识产权盗窃。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Cellebrite DI</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity</li>
<li>Canadian Penny Stocks: Can They Make You Rich?</li>
<li>Congress Beat the Market Again—Here Are the 3 Stocks They Bought</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>Go on a Shopping Spree With 3 Top Retail ETFs</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Cellebrite DI</li>
<li>投资的股票类型有不同</li>
<li>预计 2025 年上涨超过 20%，这三只股票正在提升回购能力</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>国会再次超越市场——这是他们购买的三只股票</li>
<li>消费者可选股票解析</li>
<li>与三只顶级零售 ETF 一起购物</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CLBT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 CLBT 吗？</strong> 访问 HoldingsChannel.com 获取 Cellebrite DI Ltd.（NASDAQ:CLBT - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CLBT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cellebrite DI Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cellebrite DI 吗？</h2>
</div><p>Before you consider Cellebrite DI, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cellebrite DI 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Cellebrite DI 并不在名单上。</p>
</div><p>While Cellebrite DI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cellebrite DI 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Crescent Park Management L.P. 减少了其在 Cellebrite DI Ltd. $CLBT 的持仓